Why GLP-1s and Hormone Therapy Work Better Together Heres where it gets exciting: a 2024 study published in Menopause found that postmenopausal women who were on both semaglutide (the brand name for this is Ozempic) and hormone therapy (HT) lost significantly more weight than those on semaglutide alone
Q: How can I reduce hair loss while on retatrutide or similar GLP-1 drugs
Blood glucose, food intake, and major tissues including brown adipose, liver, and spleen weights were similar between RETA and SEMA, yet RETA uniquely reduced adiposity and delayed tumor latency suggesting that targeting a single receptor GLP1R was effective for many physiologic and metabolic benefits, but the additional agonism of GIPR and GPCR by RETA uniquely impacted adiposity, tumor onset, and tumor progression
Careful and targeted patient selection are required, alongside robust education and novel technologies to monitor glucose and ketone levels to mitigate the risks and enhance the beneficial effects of SGLT2i and GLP-1 RA therapy
What Experts Are Watching Next The medical community is keeping a close eye on several key variables as next-generation obesity medications move through development pipelines: Long-Term Cardiovascular Outcomes: Major trials are underway to confirm that retatrutides multi-agonist profile translates into a lower risk of stroke, heart attack, and cardiovascular death
Exercise helps support cardiovascular health, preserve muscle mass, and improve long-term health outcomes
